AMRN has been on a tear on Tuesday and has gone up by as much as 13% as Amarin Corporation plc (NASDAQ:AMRN) raised its projections for the company’s revenues for the year 2019.
Revenue Projection BoostEarlier, the company projected revenues of $350 million for the year, but following the soaring demand for its product Vascepa, Amarin has raised the guidance to a range between $380 million and $480 million. It goes without saying that this is a significant upgrade in the company’s outlook on the back of rising demand for one product, so the associated ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals. Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer.